Dark

Check out our Level2View

SPRC
SciSparc Ltd.
stock NASDAQ

At Close

Jul 20, 2026 11:30:42 AM EDT

5.00USD+6.383%(+0.30)9,120

3.95Bid 5.48Ask 1.53Spread

Pre-market

Jul 17, 2026 9:28:30 AM EDT

5.20USD+10.638%(+0.50)0

After-hours

Jul 20, 2026 4:14:30 PM EDT

4.70USD-6.000%(-0.30)388

OverviewHistoricalExchangesShortsNews

Jan 27, 2022

08:40AM EST SciSparc Appoints Oz Adler As CEO Benzinga

08:31AM EST SciSparc Presents New Leadership Lineup PR Newswire

Jan 18, 2022

08:14AM EST SciSparc Advances Its Phase IIb Clinical Trial In Patients With Tourette Syndrome With Its Proprietary Drug Candidate SCI-110 Benzinga

08:03AM EST SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette PR Newswire

Jan 11, 2022

08:31AM EST SciSparc Exploring Psychedelics as Possible Avenue to Expand Its IP Portfolio PR Newswire

Jan 6, 2022

09:10AM EST SciSparc Highlights Recruitment Of First Patient For Its Phase 2a Trial In Alzheimer's Disease Benzinga

09:02AM EST SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical PR Newswire

Jan 4, 2022

08:44AM EST SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous PR Newswire

08:44AM EST SciSparc Says 'Patent Extends Protection For Its Novel Compounds Methods Already Granted In Australia And Japan' Benzinga

08:44AM EST SciSparc Issued U.S Patent 'Combinations Of Cannabinoids And N-Acylethanolamines' For Its Core Technology That Treats Central Nervous System Disorders Benzinga

Dec 29, 2021

09:01AM EST SciSparc Provides Updates Upon Conclusion of 2021 PR Newswire

Dec 22, 2021

08:37AM EST SciSparc Reports Will Begin Trading On Nasdaq Dec. 22, Under Ticker 'SPRC' Benzinga

08:31AM EST SciSparc's Ordinary Shares to Commence Trading on Nasdaq Capital Market Today PR Newswire

Share